The Buzz, Issue #11 is now out! This month, we look at the phase 3 dupilumab study of pediatric asthma patients, and feature two new real-world studies of peanut immunotherapy, an investigation into reproducibility of anaphylactic symptoms sequences and the new CSACI position statement on transitioning to 0.50mg epinephrine autoinjectors.

The Buzz Issue #11, March 2022 edition, will be sent to all HIVE members by email on Tues, March 22nd, and can be accessed online here.

To view all issues of The Buzz, go to